- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 833
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more
- Conditions
- Healthy Participants
- Interventions
- REGN10933 + REGN10987, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Day and older
- Enrollment
- 3,303 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 132
- States / cities
- Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
- Conditions
- Perennial Allergic Rhinitis (PAR)
- Interventions
- LY3650150, Placebo, Standard therapy for INCS
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 26
- States / cities
- Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
- Conditions
- Migraine, Episodic Migraine
- Interventions
- Galcanezumab, Rimegepant, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 77
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more
- Conditions
- Overweight or Obesity and Elevated Liver Fat
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 23
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
- Interventions
- EFG PH20 SC, PBO
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Ixekizumab, Placebo, Adalimumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more
- Conditions
- Dermatitis, Atopic
- Interventions
- GSK1070806, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Fountain Valley, California • Pompano Beach, Florida • Fayetteville, Georgia + 3 more
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
- Conditions
- Hypertension
- Interventions
- Placebo, ALN-AGT01
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Beverly Hills, California + 44 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Certolizumab pegol
- Other · Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 32
- States / cities
- Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 1,366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Concord, California • Fresno, California + 27 more
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 80
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 72 more
- Conditions
- Healthy Volunteers, Atopic Disease
- Interventions
- XmAb7195, Placebo
- Drug
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Giant Cell Arteritis
- Interventions
- Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
- Conditions
- Psoriasis
- Interventions
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
- Conditions
- Crohn's Disease
- Interventions
- Brazikumab IV Infusion, Brazikumab SC Injection, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Interventions
- LY2127399, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2127399, Placebo Q4W, Placebo Q2W
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 107 more
- Conditions
- Nasal Polyposis
- Interventions
- Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more